With a number of acute stressors fl-endorphin is released into plasma. It is unclear if fl-endorphin is converted into any other biologically active products, nor is it clear if the rate or pathways of degradation are changed during chronic stress. To explore these issues, we incubated [3H]fl-endorphinh labeled in positions 1 and 27 with plasma from normal and chronically footshocked rats and measured the rate of conversion of the label from fl-endorphin size material to smaller size material. Initial separations were done using a G-50 molecular sieving column, with subsequent characterization and identification on HPLC. By G-50 sieving, there is a time dependent formation of only one radioactive peak. HPLC identification demonstrates 3,-endorphin and another unidentified peak. This enzymatic activity is increased in the plasma of chronically stressed rats.
Introduction
The encoding of multiple active sequences and products within one polypeptide is a general principle in peptide biology, particularly in the opioid peptide families. Thus, most peptides are synthesized as part of a large molecular weight precursor protein which is then processed to yield smaller peptide fragments. In the case of proopiomelanocortin (POMC), one of the most widely studied opioid peptide precursors, there are several instances of one active sequence contained within another active sequence (Mains et al., 1977; Roberts and Herbert, 1977) . In addition, there is evidence of tissue-specific processing of these sequences, so that, in general, some tissues such as the intermediate lobe process POMC to primarily small peptides such as fl-endorphin and a-MSH * To whom all correspondence should be addressed.
while other tissues such as the anterior lobe process POMC to primarily ACTH and fl-lipotropin (fl-LPH) (Mains and Eipper, 1979; Crine et al., 1978; Eipper and Mains, 1980) . In addition to these classically studied POMC products, other biologically active peptide fragments, particularly a-endorphin, y-endorphin and 7-MSH are contained in the POMC sequence (Burbach et al., 1980a; Guillemin et al., 1976; Nakanishi et al., 1979) . A number of acute stressors release fl-endorphin-IR from the anterior lobe of the pituitary. Of the fl-endorphin-IR released from anterior lobe, 2/3 of it is fl-endorphin size by molecular sieving (Young et al., 1986; Watson et al., 1988) . The rate of disappearance of fl-endorphin released in plasma is rapid, with estimates of the half-fife of 45 rain or less (Houghten et al., 1980) . It is unclear if fl-endorphin released into plasma is converted into any other biologically active fragments such as fl-endorphin-(1-16)(a-endorphin) or fl-endorphin-(1-17) (7-endorphin). Many peptides are degraded by serum (e.g. fetal calf serum) or plasma but this degrading activity for fl-endorphin has not been characterized in plasma. In the case of fl-endorphin degradation it is unclear if chronic drive to release or elevated glucocorticoids released subsequent to activation of the HPA axis can modulate the rate of degradation of fl-endorphin in plasma.
~,-Endorphin is a naturally occurring fragment of fl-endorphin (Austen et al., 1977b; Burbach et al., 1980a,b; 1981; Guillemin et al., 1976; Smyth and Snell, 1977) . It has been demonstrated in all known POMC producing areas, both anterior and posterior pituitary, and brain (Lissitzky et al., 1978; Jegou et al., 1979; Loeber et al., 1979; Dorsa et al., 1982; Verhoef et al., 1982a,b; Vaudry et al., 1980) , ileum (Opmeer et al., 1982) and testes (Tsong et al., 1982; Margioris et al., 1983; Cheng et al., 1985) . The formation of "t-endorphin from fl-endorphin results from proteolytic cleavage of the Leu17-PhelS bond. In most of these POMC producing areas T-endorphin production is believed to result from a specific enzyme(s): T-endorphin generating enzyme (Burbach et al., 1980b; Lebouille et al., 1984; 1987; . The conversion of fl-endorphin to y-endorphin results in a substantial loss of opioid activity but produces different behavioral properties in rats including 'neuroleptic-like' activities (De Wied and Jolles, 1982; De Wied, 1978; Van Ree et al., 1978) , many of which are retained by the non-opiate fragment des tyrosine T-endorphin. Since -/-endorphin continues to demonstrate biological activities, the conversion of fl-endorphin to T-endorphin appears to be a biotransformation rather than a degradation phenomenon. Besides T-endorphin generating enzyme, several other enzymes have been demonstrated to produce 3,-endorphin: cathepsin D, rennin and endopeptidase 24.11 (Austen and Smyth, 1977a; Smyth and Snell, 1977; Graf et al., 1979a,b; Burbach et al., 1980b) . Consequently, there is more than one source of 3,-endorphin production in vivo.
We have previously shown increased releasability of anterior lobe fl-endorphin to oCRF stimulation in vitro in chronically stressed rats which were re-stressed before decapitation (Young and Akil, 1985) and a potentiation of glucocorticoids on oCRF stimulated release in vitro in anterior pituitaries from chronically stressed rats ). Yet, in vivo both naive rats and chronically stressed rats, when challenged with an acute stress, show identical release of corticosterone, ACTH and fl-endorphin. One possible explanation would be a more rapid breakdown of fl-endorphin following release. To test this hypothesis, we examined the rate of degradation of [3H]fl-endorphin in rat plasma from control and chronically stressed rats. We now report an increased rate of degradation of fl-endorphin in chronically stressed rats and that -y-endorphin is produced during the course of this degradation.
Materials and methods
Rats received 14 days of chronic intermittent footshock as previously described (Young and Akil, 1985) . Briefly, this stress paradigm consists of daily 30 min stress sessions of intermittent footshock (1.5 mA, 12 shocks/min and 1 s duration). Blood was collected following decaptitation in either EDTA or heparin tubes from control and chronic footshock stress rats. Following centrifugation, the plasma was pooled from eight rats/ group and equilibrated at 37°C in a Dubnoff Shaking metabolic incubator. Double labeled (positions 1 and 27) [3H]fl-endorphin (human) synthesized by one of us (RH), and was repurified on HPLC within 2 weeks of the experiments. It was mixed with unlabeled fl-endorphin in a 1 : 10 ratio and added in a small volume Krebs Ringer bicarbonate buffer (pH 7.4) to the plasma, producing a final concentration of fl-endorphin of 25 nM (approximately 25 000 c.p.m./ml). At time 0, 10, 20, 40 and 60 rain, aliquots were taken, acidified to pH 2.0 and frozen on dry ice and stored at -80 o C. The samples were later extracted with Sep Pak C18 cartridges as previously described for fl-endorphin extraction (Cahill et al., 1983) . To determine recovery, both the effluent and the eluate were counted for. radioactivity in a Beckman LS 9000 Liquid Scintillation Counter. After lyophilization, the samples were resuspended in 1% formic acid and applied to a 1% formic acid G-50 molecular sieving column for separation by molecular size. Half of each fraction was counted for radioactivity. The remainder of the radioactive fractions for each peak were pooled for subsequent identification by HPLC.
Two experiments were done using plasma collected in sodium EDTA. A repeat experiment used plasma from these same two groups (control and chronic footshock) collected in both sodium EDTA and sodium heparin in order to evaluate whether the method of anticoagulation affected the rate of breakdown. In addition, since corticosteroids are known to affect a number of enzymes, and daily stress sessions produced daily elevation in corticosterone, plasma from rats which received daily injection of corticosterone (30 #g/100 g body weight), or saline were compared to an unhandled non-injected control group for the rate of [3H]flendorphin conversion to products.
Final identification of the products was obtained using reverse phase HPLC. Buffer A was 50 mM potassium phosphate pH 2.7 containing 0.05 70 triethylamine. Buffer B was 100% acetonitrile. The gradient began at 570 B, increased to 2070 B over 2 min, was left constant for 2 min then raised to 45% B over 25 min. a-and ~-endorphin were used as HPLC standards as well as fl-endorphin-(18-31). The a-and "~,-endorphin were obtained from Organon (Netherlands), the fl-endorphin-(18-31) from Peninsula (Belmont, CA).
Results
Because the [3H]fl-endorphin was labelled in two positions (positions No. 1 and No. 27), two radioactive fragments would be expected from most enzymatic cleavages. When we applied the radioactive extracted plasma to G-50 column, only two peaks were seen, one eluting with fl-endorphin (peak No. 1), the parent compound and another smaller fragment of approximately 14-17 amino acid size (peak No. 2). A time dependent decrease in [3H]fl-endorphin was observed ( fig. 1) . Along with the time dependent decrease in [3H]fl-endorphin, there was a time dependent increase in the breakdown peak ( fig. 2 ). This conversion was accelerated in plasma from chronically stressed rats (figs. 1 and 2). If amino terminal cleavage of the initial tyrosine occurred, then [3H]tyrosine would result and this product would not bind to the Sep Pak. Analysis of the radioactivity in the Sep Pak effluent found only small amounts (less than 5% of the total radioactivity of the sample) and no time dependent increase, suggesting [3H]tyrosine formation was not occurring during the course of the incubation. We did not subject the effluent to any further analysis for characterization of this radioactivity. For further product identification, the pooled fractions from the breakdown peak were characterized on HPLC. The results are shown in fig.  3 . As can be seen, a proportion of the radioactivity co-migrates with 3,-endorphin on HPLC. In addition, there is another unidentified peak. In the control plasma, the ratio of ~/-endorphin to the unidentified peak is 1:2.2. In the chronic stress (table 1B, fig. 4 ), but the accelerated degradation rate of fl-endorphin in plasma from chronically stressed rats was still observed. These data suggest that (1) 
233
plasma did not differ between groups since the study was conducted 24 h after the last injection.
Discussion
In summary, we have demonstrated that the degradation of [3H]fl-endorphin is accelerated in rats which had received chronic footshock treatment. In addition, one-third of the radiolabeled product co-migrated with y-endorphin on HPLC. Although only one-third of the degradation product co-migrates with -/-endorphin following footshock stress, the amount of non-acetylated fl-endorphin released from anterior lobe is approximately 133 fmol/ml which could yield 45 fmol/ml of y-endorphin. Both y-and fl-endorphin have known opiate activity, but y-endorphin is much less potent than fl-endorphin at the opiate receptor. It does, however, have a different non-opioid set of behavioral effects (De Wied and Jolles, 1982; De Wied, 1978; Van Ree et al., 1978) . Thus, this conversion of fl-endorphin to T-endorphin may act to both modulate the opioid effects of fl-endorphin as well a encode a different message unique to 7-endorphin. The nature of the enzyme responsible for this conversion is unclear; however, given the lysosomal nature of cathepsin D, it is likely that this enzyme may be present in plasma.
The major metabolite (2/3 of the radioactivity on HPLC purification) remains unidentified. It is a fragment that is more hydrophobic than y-endorphin, fl-endorphin-(1-18), or fl-endorphin-(1-21) (Burbach et al., 1981) . It also is not the C terminal (fl-endorphin-(18-31) by HPLC identification. Thus, at the current time we are unable to identify this fragment, and whether it represents the N or C terminal of fl-endorphin. However, the demonstration of this fragment may suggest that there is cleavage of fl-endorphin at a site other than the Leua7-Phe18 bond. Thus another enzyme may be responsible for this cleavage in plasma. Whether one enzyme is responsible for the formation of both this major metabolite and T-endorphin in plasma is also unclear. If these two metabolites are generated by two different enzymes (e.g. cathepsin D and another enzyme) then both enzymatic activities are induced with chronic stress, and the ratio of T-endorphin to the major metabolite remains constant across time points, suggesting a degree of co-regulation. Alternatively, one enzyme with differential preferences for these sites could be responsible for the formation of both metabolities.
The demonstrated degradation of fl-endorphin to other products in the bloodstream suggests that 'steady state' plasma measures even following stress may not give a true picture of release but only reflect a balance between release and degradation. In addition, the fact that this process is induced during chronic stress resulting in a shorter half-life of circulating materials demonstrates that there are, even at this level, regulatory elements to prevent 'over secretion'.
This level of regulation represents only one of numerous alterations in the hypothalamo-pituitary adrenal axis following repeated stress. Using this same stress model system we have previously shown (1) a 2-fold increase in ACTH and fl-endorphin anterior pituitary content in chronically stressed animals (Young and Akil, 1985) , (2) an increase in POMC mRNA in these rats (Shiomi et al., 1986) , (3) the preferential secretion of fl-endorphin from anterior lobe in vivo with stress or in vitro in anterior pituitary cell suspensions (Young et al., 1986) , and (4) increased releasability of fl-endorphin to oCRF in pituitary cell suspensions from chronically stressed rats which are re-stressed prior t6 sacrifice (Young and Akil, 1985) . Despite these alterations, the chronically stressed animals show plasma fl-endorphin at the end of 30 min of stress identical to those of a naive rat similarly stressed. The current data suggest that accelerated breakdown of fl-endorphin in vivo may account for our failure to detect increased fl-endorphin release in these chronically stressed rats. The possible increased activity of a non-specific lysosomal enzyme such as cathepsin D in chronic stress suggests that ACTH may likewise be subject to a similar increase in the degradation in vivo. If the increased enzymatic activity results from 'T-endorphin generating enzyme', this enzyme also shows high affinity for ACTH (Lebouille et al., 1987) , and has been shown to be regulated in both anterior pituitary, intermediate pituitary and hypothalamus by glucocorticoids (Lebouille et al., 1988) . Thus, such an induction of T-endorphin generating activity with chronic stress may have importance for other hypothalamic pituitary adrenal axis hormones.
